Immune Monitoring Core

肿瘤的主动免疫治疗是肿瘤学中发展最快的领域之一。的 免疫监测核心实验室的建立是为了为需要监测的研究者提供资源 免疫治疗试验IMCL占地700平方英尺的实验室空间，两个相邻的100平方英尺的细胞培养室 免疫学研究中心（CCIR）作为最先进的设施， 实验室将在临床试验过程的所有阶段与每位研究者密切合作， 免疫监测测定的类型和适合于每个特定临床试验的数据点的数量， 处理标本、进行化验和提供数据解释方面的帮助。IMCL还允许 研究人员使用专用设备通常不会在个别实验室。作为这项承诺的一部分 为了向所有研究人员提供最新的免疫监测技术，IMCL与行业合作， 和学术合作者开发新的检测方法，验证免疫检测方法，并设定严格的质量标准， 控制标准IMCL用于免疫监测的技术包括：1）细胞因子ELISPOT 分析; 2）使用HLA I类和II类肽四聚体/多聚体的6色FACS表型分析; 3） 细胞内细胞因子染色方法; 4）先进的基于ELISA的技术， 单个样品或反应中的细胞因子（多重细胞因子分析）; 5）更新的T细胞增殖测定 使用与FACS偶联的CFSE标记; 6）更灵敏的非放射性方法来确定抗原特异性 使用FACS测定CTL活性。IMCL在临床试验开发中起着关键作用。前一 在资助期间，IMCL服务被来自19个CCSG项目中的8个项目的10名研究者使用。90%的 用户有同行审查的资金，占利用率的80.7%。未来计划的重点是 增加IMCL在CCSG相关临床研究中的参与，以及开发新的检测方法， 提高从临床试验中获得的信息的数量和质量。

Active immunotherapy to treat human cancer is one of the most rapidly developing fields in oncology. The Immune Monitoring Core Laboratory was established as a resource for investigators needing to monitor immunotherapy trials. The IMCL occupies 700 sq ft lab space with two adjacent 100 sq ft cell culture rooms in the new Center for Immunology Research (CCIR) facility. Created as a state-of-the-art facility, the goal of the lab is to work closely with each investigator at all stages of the clinical trial process by planning both the types of immune monitoring assays and number of data points suitable for each particular clinical trial, processing specimens, performing assays, and providing help with data interpretation. The IMCL also allows researchers to use dedicated equipment not usually available in individual labs. As part of this commitment to offer the most recent technology in immune monitoring to all researchers, the IMCL teams with industry and academic collaborators to develop new assays, to validate immune assays and to set rigorous quality control standards. The techniques used by the IMCL for immune monitoring include 1) cytokine ELISPOT assays; 2) 6-color FACS phenotyping assays using HLA class I and class II peptide tetramers/multimers; 3) intracellular cytokine staining methods; 4) advanced ELISA-based technology that measures multiple cytokines in a single sample or reaction (multiplex cytokine analysis); 5) newer T-cell proliferation assays using CFSE labeling coupled to FACS; 6) more sensitive non-radioactive methods to determine antigenspecific CTL activity using FACS. The IMCL plays a key role in clinical trial development. During the previous funding period, IMCL services were used by 10 investigators from 8 of the 19 CCSG programs. 90 % of users had peer-reviewed funding and accounted for 80.7 % of utilization. Future plans are focused on Increasing the IMCL participation in CCSG-related clinical studies, as well as developing new assays to improve the amount and quality of information that can be obtained from a clinical trial.